Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 89

1.

The Servier oncology pipeline in 2017.

Therasse P, Perron B, Novack SA, Abastado JP.

Future Oncol. 2017 Apr 21. doi: 10.2217/fon-2017-0129. [Epub ahead of print]

2.

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.

Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EG; RECIST working group.

Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2. Review.

PMID:
28271869
3.

Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).

Saiag P, Gutzmer R, Ascierto PA, Maio M, Grob JJ, Murawa P, Dreno B, Ross M, Weber J, Hauschild A, Rutkowski P, Testori A, Levchenko E, Enk A, Misery L, Vanden Abeele C, Vojtek I, Peeters O, Brichard VG, Therasse P.

Ann Oncol. 2016 Oct;27(10):1947-53. doi: 10.1093/annonc/mdw291. Epub 2016 Aug 8.

4.

RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group.

Schwartz LH, Seymour L, Litière S, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, de Vries E.

Eur J Cancer. 2016 Jul;62:138-45. doi: 10.1016/j.ejca.2016.03.082. Epub 2016 May 26.

PMID:
27237360
5.

RECIST 1.1-Update and clarification: From the RECIST committee.

Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, Seymour L.

Eur J Cancer. 2016 Jul;62:132-7. doi: 10.1016/j.ejca.2016.03.081. Epub 2016 May 14.

PMID:
27189322
6.

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.

Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, Jassem J, Yoshimura M, Dahabreh J, Nakayama H, Havel L, Kondo H, Mitsudomi T, Zarogoulidis K, Gladkov OA, Udud K, Tada H, Hoffman H, Bugge A, Taylor P, Gonzalez EE, Liao ML, He J, Pujol JL, Louahed J, Debois M, Brichard V, Debruyne C, Therasse P, Altorki N.

Lancet Oncol. 2016 Jun;17(6):822-35. doi: 10.1016/S1470-2045(16)00099-1. Epub 2016 Apr 27.

PMID:
27132212
7.

Servier's pipeline in oncology: moving from research to patients.

Therasse P, Abastado JP.

Future Oncol. 2016 Mar;12(5):589-94. doi: 10.2217/fon.15.363. Epub 2016 Jan 14. No abstract available.

8.

Rates of MAGE-A3 and PRAME expressing tumors in FFPE tissue specimens from bladder cancer patients: potential targets for antigen-specific cancer immunotherapeutics.

Lerut E, Van Poppel H, Joniau S, Gruselle O, Coche T, Therasse P.

Int J Clin Exp Pathol. 2015 Aug 1;8(8):9522-32. eCollection 2015.

9.

Recommendations for capture, validation and summarisation of data from studies using RECIST.

Paules M, Casey M, Williams G, Swann RS, Murphy PS, Salazar VM, Foose D, Bailey B, Therasse P.

Eur J Cancer. 2011 Mar;47(5):697-701. doi: 10.1016/j.ejca.2010.12.023.

PMID:
21300537
10.

Pattern of care in locally advanced breast cancer: focus on local therapy.

Sinacki M, Badzio A, Wełnicka-Jaśkiewicz M, Bogaerts J, Piccart MJ, Therasse P, Smith IE, Hatschek T, Jassem J.

Breast. 2011 Apr;20(2):145-50. doi: 10.1016/j.breast.2010.08.008. Epub 2010 Sep 25.

PMID:
20870406
11.

Improving cancer outcomes through international collaboration in academic cancer treatment trials.

Trimble EL, Abrams JS, Meyer RM, Calvo F, Cazap E, Deye J, Eisenhauer E, Fitzgerald TJ, Lacombe D, Parmar M, Seibel N, Shankar L, Swart AM, Therasse P, Vikram B, von Frenckell R, Friedlander M, Fujiwara K, Kaplan RS, Meunier F.

J Clin Oncol. 2009 Oct 20;27(30):5109-14. doi: 10.1200/JCO.2009.22.5771. Epub 2009 Aug 31. Review.

12.

Lessons learned from independent central review.

Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J.

Eur J Cancer. 2009 Jan;45(2):268-74. doi: 10.1016/j.ejca.2008.10.031.

PMID:
19101138
13.

Recommendations for the assessment of progression in randomised cancer treatment trials.

Dancey JE, Dodd LE, Ford R, Kaplan R, Mooney M, Rubinstein L, Schwartz LH, Shankar L, Therasse P.

Eur J Cancer. 2009 Jan;45(2):281-9. doi: 10.1016/j.ejca.2008.10.042.

PMID:
19097775
14.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J.

Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.

PMID:
19097774
15.

Individual patient data analysis to assess modifications to the RECIST criteria.

Bogaerts J, Ford R, Sargent D, Schwartz LH, Rubinstein L, Lacombe D, Eisenhauer E, Verweij J, Therasse P; RECIST Working Party.

Eur J Cancer. 2009 Jan;45(2):248-60. doi: 10.1016/j.ejca.2008.10.027. Epub 2008 Dec 16.

PMID:
19095437
16.

Evaluation of lymph nodes with RECIST 1.1.

Schwartz LH, Bogaerts J, Ford R, Shankar L, Therasse P, Gwyther S, Eisenhauer EA.

Eur J Cancer. 2009 Jan;45(2):261-7. doi: 10.1016/j.ejca.2008.10.028. Epub 2008 Dec 16.

PMID:
19091550
17.

Cancer clinical trial outcomes: any progress in tumour-size assessment?

Verweij J, Therasse P, Eisenhauer E; RECIST working group.

Eur J Cancer. 2009 Jan;45(2):225-7. doi: 10.1016/j.ejca.2008.10.025. Epub 2008 Dec 8.

PMID:
19068275
18.

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.

Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, Piccart MJ, Bogaerts J, Therasse P.

J Clin Oncol. 2008 Oct 20;26(30):4883-90. doi: 10.1200/JCO.2007.14.4659. Epub 2008 Sep 15.

19.

Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Lück HJ, Mackey JR, Nabholtz JM, Paridaens R, Biganzoli L, Jassem J, Bontenbal M, Bonneterre J, Chan S, Basaran GA, Therasse P.

J Clin Oncol. 2008 Apr 20;26(12):1987-92. doi: 10.1200/JCO.2007.10.8407.

PMID:
18421050
20.

Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.

Piccart-Gebhart MJ, Burzykowski T, Buyse M, Sledge G, Carmichael J, Lück HJ, Mackey JR, Nabholtz JM, Paridaens R, Biganzoli L, Jassem J, Bontenbal M, Bonneterre J, Chan S, Basaran GA, Therasse P.

J Clin Oncol. 2008 Apr 20;26(12):1980-6. doi: 10.1200/JCO.2007.10.8399.

PMID:
18421049

Supplemental Content

Loading ...
Support Center